Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
So C4X Discovery Holdings plc received a USD11.0 million milestone payment from FTSE 100-listed pharmaceutical firm AstraZeneca PLC, following trials of the C4X respiratory disease therapy treatment. The payment stems from preclinical progress of C4X's NRF2 Activator programme, an oral therapy for the treatment of inflammatory and respiratory diseases which AstraZeneca is developing following a agreement between the two in November. In addition to a USD2.0 million upfront payment, the global licencing agreement for the NRF2 Activator entitles C4X to receive up to USD400.0 million in payments following preclinical, clinical development and commercial milestones. The deal also will grant C4X tiered mid-single digit royalties on future sales of the NRF2.
This share is so undervalued now, so can't wait to top up on my holding ! There does not appear to be a better investment out there except maybe Futura Medical. Perhaps split any available monies between both of these.
Just to add that they 2 of these arrangements in place, second is with sanofi. Same numbers but in euros not dollars.
It's "UP TO"
Recent Developments
Last Updated: 03/01/2024
C4XD announced a significant ($11m) milestone payment from AstraZeneca on 3 January, under a licensing deal with Astra Zeneca, signed in November 2022. Under the agreement, AstraZeneca received an exclusive global licence for the NRF2 Activator programme. In return, C4XD received a $2m upfront payment and is eligible for pre-clinical milestone payments totalling $14m and a further $386m in clinical and commercial milestone payments. AstraZeneca are developing the drug as a treatment for a number of inflammatory conditions and the market for these is worth $60bn. The category includes Sickle Cell Disease, IBD and lung diseases such as COPD. We shall be meeting the CEO later in January.
Wow I was a little up here as recently as 8th January this year , when it spiked to 18p.
The AIM casino .
RNS listing cancelled today yesterday was last day maybe the 27% rise shorters closing .
What 400 million dollars are you referring too ripley
Dannatt , what do you mean ?
Sorry. Cracking up. Yes I see what you mean. Hopefully many multiples of this price in a year or two.